Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,447.00GBp
18 Aug 2017
Change (% chg)

-34.00 (-0.76%)
Prev Close
4,481.00
Open
4,477.00
Day's High
4,500.47
Day's Low
4,418.50
Volume
1,751,203
Avg. Vol
2,500,426
52-wk High
5,585.07
52-wk Low
3,996.00

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.06
Market Cap(Mil.): £56,829.93
Shares Outstanding(Mil.): 1,265.80
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 18.89 31.59 32.70
EPS (TTM): 2.38 -- --
ROI: 7.86 15.32 14.88
ROE: 28.47 16.34 16.12

FDA expands use of AstraZeneca/Merck ovarian cancer drug

The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.

Aug 17 2017

UPDATE 1-FDA expands use of AstraZeneca/Merck ovarian cancer drug

Aug 17 The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.

Aug 17 2017

FDA approves expanded use of AstraZeneca ovarian cancer drug

Aug 17 The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.

Aug 17 2017

BRIEF-Astrazeneca says non-exec director Burlington to retire

* BRUCE BURLINGTON WILL RETIRE AS A NON-EXECUTIVE DIRECTOR OF ASTRAZENECA PLC Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

Aug 16 2017

Deals of the day-Mergers and acquisitions

Aug 1 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Aug 01 2017

Fitch Downgrades AstraZeneca to 'A-'; Outlook Negative

(The following statement was released by the rating agency) LONDON, August 01 (Fitch) Fitch Ratings has downgraded UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating to 'A-' from 'A'. The Outlook is Negative. The downgrade reflects AstraZeneca's increasing business risk as the pharmaceutical group transitions into next-generation therapies. The company's recent mixed late-stage pipeline developments in oncology - an increasing

Aug 01 2017

AstraZeneca a tricky takeover target after big cancer drug blow

LONDON Hurdles ranging from existing commercial tie-ups to politics make drugmaker AstraZeneca a problematic takeover target in the wake of last week's big lung cancer setback that hammered the stock and rekindled takeover talk.

Aug 01 2017

AstraZeneca gets breakthrough status for blood cancer drug

LONDON AstraZeneca said on Tuesday that U.S. regulators had awarded its blood cancer drug acalabrutinib "breakthrough" status for the treatment of patients with mantle cell lymphoma, a rare type of blood cancer.

Aug 01 2017

AstraZeneca gets breakthrough status for blood cancer drug

LONDON, Aug 1 AstraZeneca said on Tuesday that U.S. regulators had awarded its blood cancer drug acalabrutinib "breakthrough" status for the treatment of patients with mantle cell lymphoma, a rare type of blood cancer.

Aug 01 2017

AstraZeneca fights back in cancer with new hires, fast drug status

LONDON AstraZeneca hired two senior scientists to bolster its cancer drug work on Monday, signaling confidence in its oncology portfolio despite last week's big setback in a lung cancer clinical trial.

Jul 31 2017

Earnings vs. Estimates